GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MYND Life Sciences Inc (XCNQ:MYND) » Definitions » ROA %

MYND Life Sciences (XCNQ:MYND) ROA % : -212.32% (As of Jul. 2024)


View and export this data going back to 2021. Start your Free Trial

What is MYND Life Sciences ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. MYND Life Sciences's annualized Net Income for the quarter that ended in Jul. 2024 was C$-1.52 Mil. MYND Life Sciences's average Total Assets over the quarter that ended in Jul. 2024 was C$0.71 Mil. Therefore, MYND Life Sciences's annualized ROA % for the quarter that ended in Jul. 2024 was -212.32%.

The historical rank and industry rank for MYND Life Sciences's ROA % or its related term are showing as below:

XCNQ:MYND' s ROA % Range Over the Past 10 Years
Min: -214.62   Med: -209.09   Max: -81.31
Current: -81.31

During the past 3 years, MYND Life Sciences's highest ROA % was -81.31%. The lowest was -214.62%. And the median was -209.09%.

XCNQ:MYND's ROA % is ranked worse than
76.62% of 1497 companies
in the Biotechnology industry
Industry Median: -34.49 vs XCNQ:MYND: -81.31

MYND Life Sciences ROA % Historical Data

The historical data trend for MYND Life Sciences's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MYND Life Sciences ROA % Chart

MYND Life Sciences Annual Data
Trend Oct21 Oct22 Oct23
ROA %
-163.56 -214.62 -209.09

MYND Life Sciences Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -607.73 329.12 -190.18 -140.64 -212.32

Competitive Comparison of MYND Life Sciences's ROA %

For the Biotechnology subindustry, MYND Life Sciences's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MYND Life Sciences's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MYND Life Sciences's ROA % distribution charts can be found below:

* The bar in red indicates where MYND Life Sciences's ROA % falls into.


;
;

MYND Life Sciences ROA % Calculation

MYND Life Sciences's annualized ROA % for the fiscal year that ended in Oct. 2023 is calculated as:

ROA %=Net Income (A: Oct. 2023 )/( (Total Assets (A: Oct. 2022 )+Total Assets (A: Oct. 2023 ))/ count )
=-1.518/( (0.654+0.798)/ 2 )
=-1.518/0.726
=-209.09 %

MYND Life Sciences's annualized ROA % for the quarter that ended in Jul. 2024 is calculated as:

ROA %=Net Income (Q: Jul. 2024 )/( (Total Assets (Q: Apr. 2024 )+Total Assets (Q: Jul. 2024 ))/ count )
=-1.516/( (0.708+0.72)/ 2 )
=-1.516/0.714
=-212.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jul. 2024) net income data. ROA % is displayed in the 30-year financial page.


MYND Life Sciences  (XCNQ:MYND) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Jul. 2024 )
=Net Income/Total Assets
=-1.516/0.714
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-1.516 / 0)*(0 / 0.714)
=Net Margin %*Asset Turnover
=N/A %*0
=-212.32 %

Note: The Net Income data used here is four times the quarterly (Jul. 2024) net income data. The Revenue data used here is four times the quarterly (Jul. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


MYND Life Sciences ROA % Related Terms

Thank you for viewing the detailed overview of MYND Life Sciences's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


MYND Life Sciences Business Description

Traded in Other Exchanges
Address
105-2248 Elgin Avenue, Port Coquitlam, BC, CAN, V3C 2B2
MYND Life Sciences Inc is a medical biotech drug research and development company. The company is focused on neuro pharmaceutical and novel drug development, diagnostics, and vaccines and is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by different molecular concepts for the applications of psilocybin analogs for overcoming diseases.